PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Clover Biopharmaceuticals Ltd (2197.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG2280A1076
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$537.04M
Revenue (TTM)HK$257.00K
Gross Profit (TTM)-HK$475.64M
EBITDA (TTM)-HK$2.99B
Year RangeHK$0.39 - HK$2.04
Target PriceHK$3.91

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Clover Biopharmaceuticals Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Clover Biopharmaceuticals Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-49.25%
15.90%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Clover Biopharmaceuticals Ltd had a return of -43.55% year-to-date (YTD) and -81.28% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-43.55%6.12%
1 month-19.54%-1.08%
6 months-49.28%15.73%
1 year-81.28%22.34%
5 years (annualized)N/A11.82%
10 years (annualized)N/A10.53%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-29.03%6.82%-12.77%
2023-34.75%-14.29%7.58%-12.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 2197.HK is 7, indicating that it is in the bottom 7% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of 2197.HK is 77
Clover Biopharmaceuticals Ltd(2197.HK)
The Sharpe Ratio Rank of 2197.HK is 99Sharpe Ratio Rank
The Sortino Ratio Rank of 2197.HK is 33Sortino Ratio Rank
The Omega Ratio Rank of 2197.HK is 66Omega Ratio Rank
The Calmar Ratio Rank of 2197.HK is 66Calmar Ratio Rank
The Martin Ratio Rank of 2197.HK is 1111Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Clover Biopharmaceuticals Ltd (2197.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


2197.HK
Sharpe ratio
The chart of Sharpe ratio for 2197.HK, currently valued at -0.87, compared to the broader market-2.00-1.000.001.002.003.00-0.87
Sortino ratio
The chart of Sortino ratio for 2197.HK, currently valued at -2.13, compared to the broader market-4.00-2.000.002.004.006.00-2.13
Omega ratio
The chart of Omega ratio for 2197.HK, currently valued at 0.78, compared to the broader market0.501.001.500.78
Calmar ratio
The chart of Calmar ratio for 2197.HK, currently valued at -0.81, compared to the broader market0.001.002.003.004.005.00-0.81
Martin ratio
The chart of Martin ratio for 2197.HK, currently valued at -1.34, compared to the broader market-10.000.0010.0020.0030.00-1.34
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.89, compared to the broader market-2.00-1.000.001.002.003.001.89
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.006.002.74
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.001.002.003.004.005.001.43
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.65, compared to the broader market-10.000.0010.0020.0030.007.65

Sharpe Ratio

The current Clover Biopharmaceuticals Ltd Sharpe ratio is -0.87. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.87
1.87
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

Dividends

Dividend History


Clover Biopharmaceuticals Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-97.53%
-3.64%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Clover Biopharmaceuticals Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Clover Biopharmaceuticals Ltd was 97.53%, occurring on Apr 15, 2024. The portfolio has not yet recovered.

The current Clover Biopharmaceuticals Ltd drawdown is 97.53%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.53%Dec 14, 2021573Apr 15, 2024
-29.97%Nov 8, 20213Nov 10, 202121Dec 9, 202124

Volatility

Volatility Chart

The current Clover Biopharmaceuticals Ltd volatility is 16.27%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2024FebruaryMarchApril
16.27%
3.47%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Clover Biopharmaceuticals Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items